Prominent British scientist, Dr. Kirsty Smitten, known for her groundbreaking work in the development of antibiotics, passed away from cancer at the age of 29. Dr. Smitten, the co-founder and CEO of MetalloBio, was recognized for her efforts to address antimicrobial resistance (AMR), which has rendered many antibiotics ineffective. Her significant contributions earned her a spot on Forbes’ 30 under 30 Europe list in 2020.
Before her demise, Dr. Smitten was deeply involved in her research, even during her treatments, as a PhD researcher at the University of Sheffield. Diagnosed with cardiac angiosarcoma, a rare heart tumor, in late January, she continued her relentless work, driven by a deep-rooted desire to save lives.
MetalloBio, the company co-founded by Kirsty, continues its mission to counteract AMR, a global challenge responsible for approximately 1.2 million deaths annually. The World Health Organization has highlighted this as an “urgent priority”.
Beyond her professional achievements, Kirsty’s compassionate nature extended to providing support for fellow cancer patients. Many individuals, post her passing, expressed their gratitude online, highlighting how she had been an instrumental pillar of strength for them during their cancer battles.
Matt added, “We were astounded by the overwhelming messages and stories shared by cancer patients, highlighting Kirsty’s selfless support. Her humility was such that she never spoke of these acts, but her impact on the community was truly profound.”
The Smitten family aims to ensure that Kirsty’s legacy thrives both through MetalloBio’s endeavors and a charity they intend to establish in her name. A fundraiser for the proposed charity has already been initiated.
